1 – 7 of 7
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
The Progression of Mycosis Fungoides During Treatment with Mogamulizumab: A BIO-MUSE Case Study of the Tumor and Immune Response in Peripheral Blood and Tissue
(
- Contribution to journal › Article
- 2024
-
Mark
Evaluation of the applicability of GARDskin to predict skin sensitizers in extracts from medical device materials
(
- Contribution to journal › Article
-
Mark
CD163+ macrophages in mantle cell lymphoma induce activation of prosurvival pathways and immune suppression
(
- Contribution to journal › Article
- 2020
-
Mark
The GARDpotency Assay for Potency-Associated Subclassification of Chemical Skin Sensitizers—Rationale, Method Development, and Ring Trial Results of Predictive Performance and Reproducibility
(
- Contribution to journal › Article
- 2019
-
Mark
Validation of the GARD™skin Assay for Assessment of Chemical Skin Sensitizers : Ring Trial Results of Predictive Performance and Reproducibility
(
- Contribution to journal › Article
- 2018
-
Mark
Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity
(
- Contribution to journal › Article
- 2017
-
Mark
Evaluation of the GARD assay in a blind cosmetics Europe study
(
- Contribution to journal › Article